Is Zoetis’ Raised Earnings Guidance and Share Buyback Changing the Investment Case for ZTS?

• Zoetis recently reported second-quarter 2025 results, highlighted by sales of US$2.46 billion and net income of US$718 million, along with raised full-year 2025 earnings guidance and a completed share repurchase tranche totaling 2.14 million shares for US$336.96 million.
• These developments underscore strong operational performance and confidence in sustained earnings momentum, as Zoetis continues to invest in both shareholder returns and future growth initiatives.
• We'll examine how Zoetis' upward earnings guidance enhancement may influence the company's investment narrative and long-term outlook.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Zoetis Investment Narrative Recap

To be a Zoetis shareholder, you need to believe in the company’s ability to sustain revenue growth through product innovation, global expansion, and share leadership in animal health, despite competitive and regulatory headwinds. The recent earnings beat, upward full-year guidance, and robust share repurchase activity may reinforce confidence in Zoetis’ capacity to manage near-term margin risks, but they do not fundamentally change the largest immediate threat: competitive pressures in core franchises remain front and center for investors monitoring Zoetis’ trajectory.

Among recent announcements, the raised 2025 earnings guidance stands out as most relevant. By increasing both revenue and earnings expectations on the back of healthy year-to-date results, Zoetis is highlighting its belief in underlying demand and operational resilience, providing a near-term catalyst for those focused on profitability even as adoption hurdles and competitive risks linger.

In contrast, investors should remain aware that competition in key franchises may still present challenges to long-term margin expansion and…

Read the full narrative on Zoetis (it's free!)

Zoetis' outlook anticipates $10.9 billion in revenue and $3.2 billion in earnings by 2028. This is based on an expected annual revenue growth rate of 5.1% and a $0.6 billion increase in earnings from the current $2.6 billion level.

Uncover how Zoetis' forecasts yield a $190.62 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Eight members of the Simply Wall St Community placed fair values for Zoetis ranging from US$134 to US$191.52 per share. Investors express wide-ranging views while competitive threats in core categories continue to influence the company’s long-term prospects.

Explore 8 other fair value estimates on Zoetis - why the stock might be worth 13% less than the current price!

Build Your Own Zoetis Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zoetis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com